181 related articles for article (PubMed ID: 36462704)
1. Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Zhao H; Peng P; Luo Z; Liu H; Sun J; Wang X; Jia Q; Yang Z
Photodiagnosis Photodyn Ther; 2023 Mar; 41():103220. PubMed ID: 36462704
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
3. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
5. Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
Sun J; Ma X; Shen H; Liu B
Photodiagnosis Photodyn Ther; 2021 Jun; 34():102248. PubMed ID: 33711534
[TBL] [Abstract][Full Text] [Related]
6. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 Mar; 197(3 Pt 1):548-558. PubMed ID: 27780784
[TBL] [Abstract][Full Text] [Related]
9. Hexaminolevulinate in the Management of Nonmuscle Invasive Bladder Cancer: A Meta-Analysis.
Konecki T; Kutwin P; Łowicki R; Juszczak AB; Jabłonowski Z
Photobiomodul Photomed Laser Surg; 2019 Sep; 37(9):551-558. PubMed ID: 31339825
[No Abstract] [Full Text] [Related]
10. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
[TBL] [Abstract][Full Text] [Related]
11. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
[TBL] [Abstract][Full Text] [Related]
12. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
Yang LP
Mol Diagn Ther; 2014 Feb; 18(1):105-16. PubMed ID: 24248555
[TBL] [Abstract][Full Text] [Related]
13. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.
Kausch I; Sommerauer M; Montorsi F; Stenzl A; Jacqmin D; Jichlinski P; Jocham D; Ziegler A; Vonthein R
Eur Urol; 2010 Apr; 57(4):595-606. PubMed ID: 20004052
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials.
Yuan H; Qiu J; Liu L; Zheng S; Yang L; Liu Z; Pu C; Li J; Wei Q; Han P
PLoS One; 2013; 8(9):e74142. PubMed ID: 24058522
[TBL] [Abstract][Full Text] [Related]
16. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
[TBL] [Abstract][Full Text] [Related]
18. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).
Bader MJ; Stepp H; Beyer W; Pongratz T; Sroka R; Kriegmair M; Zaak D; Welschof M; Tilki D; Stief CG; Waidelich R
Urol Oncol; 2013 Oct; 31(7):1178-83. PubMed ID: 22440147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
